Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy
- PMID: 17497466
- PMCID: PMC2409178
- DOI: 10.1080/08860220701260511
Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy
Abstract
Background: Treatment options for progressive IgA nephropathy are limited.
Methods: We performed a small, randomized controlled trial to evaluate the effects of prednisolone (PSL, 30 mg/dL, gradually tapered to 5 mg/dL over two years) plus 50 mg/day of losartan (LST, an angiotensin II receptor blocker) or PSL alone on IgA nephropathy. We separated 38 patients (age, 33 +/- 11 years; creatinine clearance, 103 +/- 31 mL/min; proteinuria, 1.6 +/- 0.5 g/day) into two groups that were treated with either PSL plus LST or PSL alone, and compared the proteinuria and creatinine clearance after two years. Baseline and histopathological data did not significantly differ between the two groups.
Results: Two years of treatment in both groups significantly decreased proteinuria compared with baseline, and PSL plus LST (from 1.6 +/- 0.6 to 0.3 +/- 0.1 g/day, p < 0.05) was more effective than PSL alone (from 1.6 +/- 0.3 to 0.5 +/- 0.1 g/day, p < 0.05). Creatinine clearance in both groups was similar at the start of study but significantly differed at the end of the study (PSL plus LST, 104.3 +/- 36.4 to 100.4 +/- 38.9 mL/min; PSL alone, 103.4 +/- 28.5 to 84.8 +/- 34.3 mL/min, p < 0.05).
Conclusions: Combined therapy with PSL plus LST appears to be more effective than PSL alone in reducing proteinuria and protecting renal function in patients with IgA nephropathy.
Figures



Similar articles
-
Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.Medicina (B Aires). 2007;67(5):445-50. Medicina (B Aires). 2007. PMID: 18051227 Clinical Trial.
-
Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy.Nephrology (Carlton). 2006 Oct;11(5):462-6. doi: 10.1111/j.1440-1797.2006.00665.x. Nephrology (Carlton). 2006. PMID: 17014562 Clinical Trial.
-
Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.Clin Nephrol. 2000 Jan;53(1):1-9. Clin Nephrol. 2000. PMID: 10661476
-
[Immunosuppressive therapy in IgA glomerulonephritis with chronic renal failure: case study presentation and literature review].G Ital Nefrol. 2002 Sep-Oct;19(5):523-8. G Ital Nefrol. 2002. PMID: 12439840 Review. Italian.
-
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease.Clin Exp Nephrol. 2006 Jun;10(2):136-9. doi: 10.1007/s10157-005-0403-6. Clin Exp Nephrol. 2006. PMID: 16791401 Review.
Cited by
-
Non-immunosuppressive treatment for IgA nephropathy.Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. Cochrane Database Syst Rev. 2024. PMID: 38299639 Free PMC article.
-
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.Kidney Int. 2015 Nov;88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16. Kidney Int. 2015. PMID: 26376134 Free PMC article. Review.
-
IgA Nephropathy: Beyond the Half-Century.Medicina (Kaunas). 2023 Dec 27;60(1):54. doi: 10.3390/medicina60010054. Medicina (Kaunas). 2023. PMID: 38256315 Free PMC article. Review.
-
Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy.PLoS One. 2013 Aug 19;8(8):e71545. doi: 10.1371/journal.pone.0071545. eCollection 2013. PLoS One. 2013. PMID: 23977072 Free PMC article. Clinical Trial.
-
Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.PLoS One. 2025 Jun 10;20(6):e0323530. doi: 10.1371/journal.pone.0323530. eCollection 2025. PLoS One. 2025. PMID: 40493692 Free PMC article.
References
-
- D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–727. - PubMed
-
- Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: Prognostic significance of proteinuria and histological alteration. Nephron. 1983;34:146–153. - PubMed
-
- Radford MG, Jr, Donardio JV, Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207. - PubMed
-
- Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med. 1996;334:939–945. - PubMed
-
- Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33(Suppl. 1):S16–S20. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous